The timeline of Nobivac innovations

With the revolutionary Immuno-Mist-R™ and a unique oral bivalent composition, Nobivac^® Intra-Trac^® Oral BbPi made effective oral vaccination against both Bordetella bronchiseptica and canine parainfluenza virus possible for the first time.¹

Nobivac^® DP PLUS became the first vaccine capable of breaking through any level of parvovirus maternally derived antibody (MDA) in puppies as young as four weeks old, representing a revolutionary breakthrough for puppy protection.²

Nobivac^® Respira Bb became the first subunit injectable vaccine against Bordetella bronchiseptica for dogs.³

Nobivac^® Myxo-RHD PLUS with advanced vector technology was designed to offer protection against myxomatosis and Rabbit Haemorrhagic Disease (RHD) caused by both RHDV-1 and RHDV-2.⁴

Nobivac EDGE^TM became the first low-volume vaccine range that also includes protection against canine parainfluenza, canine distemper, canine parvovirosis and canine adenovirus disease. The family of Nobivac EDGE vaccines includes Nobivac EDGE^TM DAPPv, Nobivac EDGE^TM Lepto₄ and Nobivac EDGE^TM DAPPv+L₄.^5-7

For the first time, Nobivac^® Canine Flu Bivalent provided protection against both the H3N2 and H3N8 variants in a single vaccine. This development allowed veterinarians to give dogs broader protection with a single injection.⁸

Nobivac^® Canine Flu H3N2 also became the first canine influenza vaccine to protect cats.⁹

Nobivac^® Canine Flu H3N2 was introduced in response to outbreaks of this strain, including a severe H3N2 epidemic in dogs in the Chicago area in 2015.⁹

Nobivac^® Intra-Trac Oral Bb expanded the range of canine cough vaccination options to respond to the needs of veterinarians, pet owners and canines.

Nobivac^® L4 became the first canine leptospirosis vaccine to protect against infection and urinary excretion of serovars from the four most important European Leptospira serogroups.¹⁰

Nobivac^® Myxo-RHD gave veterinarians the ability to provide rabbits with 12 months of combined protection against two untreatable and deadly diseases: myxomatosis and Rabbit Haemorrhagic Disease (RHD).¹¹

VacciPure™ filtration was introduced for Nobivac^® Lepto₄, marking a major step forward in vaccine quality. VacciPure reduces the total proteins in the vaccine, which may reduce the risk of hypersensitivity responses after vaccination^.12,13

Nobivac^® Feline 2-FeLV became the first vaccine with a 2-year duration of immunity label claim against Feline Leukaemia (FeLV), allowing veterinarians to protect cats while minimizing injections.¹⁴

Nobivac^® Lepto₄ was launched as the first vaccine with label claims against mortality and urinary shedding caused by L canicola, L grippotyphosa, L icterohaemorrhagiae and L Pomona serovars.^{13, 15-16}

Nobivac^® Lyme became the first Lyme disease vaccine proven to induce borreliacidal antibodies to Borrelia bacteria expressing either outer surface protein A (OspA ) or OspC, thus giving pets the best chance to avoid becoming infected.¹⁷

Nobivac^® Canine Flu H3N8 was introduced in response to outbreaks across the US, giving veterinarians the first vaccine to protect dogs against this serious and highly contagious disease.¹⁸

Nobivac canine parvovirus vaccines are shown to protect against the parvovirus 2c strain, allowing veterinarians to protect dogs against the most common variant in many countries worldwide.¹⁹

With an update to the registration of Nobivac^® Tricat Trio, veterinarians could provide cats with 3-year duration of immunity against feline panleukopenia, a highly contagious and often-fatal disease.²⁰

Nobivac^® Feline 3-HCP became the first feline HCP vaccine with an official 3-year duration of immunity label claim.²¹

Nobivac^® KC became the first intranasal Canine Infectious Respiratory Disease vaccine with a 1-year duration of immunity, providing a longer-lasting solution to the twin problems of Bordetella bronchiseptica and canine parainfluenza virus.²²

Nobivac^® Intra-Trac^® 3 ADT changed the administration of intranasal canine cough vaccines with needle-free Advanced Delivery Technology. Accidental subcutaneous injection of intranasal canine cough vaccines is no longer a safety issue.²³

Nobivac^® Canine 3-DAPv became the first canine core vaccine with a 3-year duration
of immunity label claim in the US.²⁴

Nobivac^® DHPPi became the world’s first vaccine to demonstrate 2-year duration of immunity for canine parvovirus, canine distemper virus and canine adenovirus. This was subsequently extended to 3 years in 2004, based once again on rigorous testing.²⁵

The launch of Nobivac^® KC gave veterinarians an intranasal vaccine to protect dogs against Canine Infectious Respiratory Disease caused by Bordetella bronchiseptica and canine parainfluenza virus. Nobivac^® KC provides protection against both diseases in a single vaccine.²²

Nobivac^® Tricat became the first feline vaccine with published evidence that it stimulates cross-protection against canine parvovirus CPV type 2b.^26,27

Nobivac^® Feline-Bb became the first feline vaccine against Bordetella bronchiseptica, which is highly contagious in cats. With needle-free administration of only 0.2 mL into one nostril, Nobivac^® Feline-Bb is still the only feline Bordetella bronchiseptica vaccine.²⁸

Nobivac^® Myxo became the first rabbit myxomatosis vaccine licensed in the UK, providing protection against this dangerous and deadly viral disease for which no treatment was available.²⁹

Nobivac^® Parvo-C became the first canine parvovirus vaccine to reliably override levels of maternal antibodies present at 12 weeks of age.³⁰

Launch of the first Nobivac (then called Nobi-vac) vaccines in the UK with the introduction of Nobi-vac D, DH and L.

We are committed to discovering
new ways to broaden protection.